Literature DB >> 18708148

Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine.

Joanna S Fowler1, Nora D Volkow, Jean Logan, David Alexoff, Frank Telang, Gene-Jack Wang, Christopher Wong, Yeming Ma, Aarti Kriplani, Kith Pradhan, David Schlyer, Millard Jayne, Barbara Hubbard, Pauline Carter, Donald Warner, Payton King, Colleen Shea, Youwen Xu, Lisa Muench, Karen Apelskog.   

Abstract

Methamphetamine is one of the most addictive and neurotoxic drugs of abuse. It produces large elevations in extracellular dopamine in the striatum through vesicular release and inhibition of the dopamine transporter. In the U.S. abuse prevalence varies by ethnicity with very low abuse among African Americans relative to Caucasians, differentiating it from cocaine where abuse rates are similar for the two groups. Here we report the first comparison of methamphetamine and cocaine pharmacokinetics in brain between Caucasians and African Americans along with the measurement of dopamine transporter availability in striatum. Methamphetamine's uptake in brain was fast (peak uptake at 9 min) with accumulation in cortical and subcortical brain regions and in white matter. Its clearance from brain was slow (except for white matter which did not clear over the 90 min) and there was no difference in pharmacokinetics between Caucasians and African Americans. In contrast cocaine's brain uptake and clearance were both fast, distribution was predominantly in striatum and uptake was higher in African Americans. Among individuals, those with the highest striatal (but not cerebellar) methamphetamine accumulation also had the highest dopamine transporter availability suggesting a relationship between METH exposure and DAT availability. Methamphetamine's fast brain uptake is consistent with its highly reinforcing effects, its slow clearance with its long-lasting behavioral effects and its widespread distribution with its neurotoxic effects that affect not only striatal but also cortical and white matter regions. The absence of significant differences between Caucasians and African Americans suggests that variables other than methamphetamine pharmacokinetics and bioavailability account for the lower abuse prevalence in African Americans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708148      PMCID: PMC2606665          DOI: 10.1016/j.neuroimage.2008.07.020

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  35 in total

1.  Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users.

Authors:  K S Kalasinsky; T Z Bosy; G A Schmunk; G Reiber; R M Anthony; Y Furukawa; M Guttman; S J Kish
Journal:  Forensic Sci Int       Date:  2001-02-15       Impact factor: 2.395

2.  Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.

Authors:  G J Rivière; W B Gentry; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration.

Authors:  R L Balster; C R Schuster
Journal:  J Exp Anal Behav       Date:  1973-07       Impact factor: 2.468

4.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

5.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; M Leonido-Yee; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; J Logan; C Wong; E N Miller
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

6.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

7.  Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain.

Authors:  N D Volkow; G J Wang; M W Fischman; R Foltin; J S Fowler; D Franceschi; M Franceschi; J Logan; S J Gatley; C Wong; Y S Ding; R Hitzemann; N Pappas
Journal:  Life Sci       Date:  2000-08-11       Impact factor: 5.037

8.  Effect of reserpine on the brain uptake of carbon 11 methamphetamine and its N-propagyl derivative, deprenyl.

Authors:  O Inoue; S Axelsson; H Lundqvist; L Oreland; B Långström
Journal:  Eur J Nucl Med       Date:  1990

9.  Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

Authors:  R B Rothman; M H Baumann; C M Dersch; D V Romero; K C Rice; F I Carroll; J S Partilla
Journal:  Synapse       Date:  2001-01       Impact factor: 2.562

10.  Structural abnormalities in the brains of human subjects who use methamphetamine.

Authors:  Paul M Thompson; Kiralee M Hayashi; Sara L Simon; Jennifer A Geaga; Michael S Hong; Yihong Sui; Jessica Y Lee; Arthur W Toga; Walter Ling; Edythe D London
Journal:  J Neurosci       Date:  2004-06-30       Impact factor: 6.167

View more
  44 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Dysregulation of dopamine and glutamate release in the prefrontal cortex and nucleus accumbens following methamphetamine self-administration and during reinstatement in rats.

Authors:  Aram Parsegian; Ronald E See
Journal:  Neuropsychopharmacology       Date:  2013-09-02       Impact factor: 7.853

3.  A stress steroid triggers anxiety via increased expression of α4βδ GABAA receptors in methamphetamine dependence.

Authors:  H Shen; A Mohammad; J Ramroop; S S Smith
Journal:  Neuroscience       Date:  2013-08-29       Impact factor: 3.590

4.  Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine.

Authors:  Noah R Gubner; Cheryl Reed; Carrie S McKinnon; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2013-08-28       Impact factor: 3.332

5.  A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence.

Authors:  Peter D Alexander; Kristina M Gicas; Taylor S Willi; Clara N Kim; Veronika Boyeva; Ric M Procyshyn; Geoff N Smith; Allen E Thornton; William J Panenka; Andrea A Jones; Fidel Vila-Rodriguez; Donna J Lang; G William MacEwan; William G Honer; Alasdair M Barr
Journal:  Psychopharmacology (Berl)       Date:  2017-02-11       Impact factor: 4.530

Review 6.  Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.

Authors:  Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2019-01-26       Impact factor: 3.533

7.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

8.  Relationship between discriminative stimulus effects and plasma methamphetamine and amphetamine levels of intramuscular methamphetamine in male rhesus monkeys.

Authors:  Matthew L Banks; Douglas A Smith; David F Kisor; Justin L Poklis
Journal:  Pharmacol Biochem Behav       Date:  2015-12-03       Impact factor: 3.533

9.  Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus.

Authors:  Jarod Swant; Sanika Chirwa; Gregg Stanwood; Habibeh Khoshbouei
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Elena Shumay; Frank Telang; Peter K Thanos; David Alexoff
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.